Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05289193
Overview
Combination treatment with nivolumab and ipilimumab before surgery may help people with melanoma because the drugs are designed to help the immune system target and destroy cancer cells (immunotherapy), which may shrink the cancer and prevent recurrence after surgery. Treatment given before surgery is called neoadjuvant therapy. The purpose of this study is to find out whether neoadjuvant therapy with nivolumab and ipilimumab can kill melanoma tumors before surgery and prevent disease from coming back after surgery. This study also explores a new, experimental PET scan that images the immune system to see if it is related to treatment outcomes.
Sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Contacts
Michael Postow, MD (Principal Investigator)
postowm@mskcc.org
646-888-4589
Neeta Pandit-Taskar
pandit-n@mskcc.org
2126393046
ClinicalTrials.gov
NCT05289193Drug / Compound
Help us improve your experience